Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R & D, Johnson & Johnson

NEW BRUNSWICK, N.J., Aug. 8, 2022 - Johnson & Johnson (NYSE: JNJ) (“the Company”) announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson’s industry-leading portfolio. The Company will continue to prioritize innovation and building new capabilities to improve the lives of the patients and consumers we serve worldwide. About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.Cautions Concerning Forward Looking StatementsThis press release co...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news